Hagedorn Research


Our Origins

The Novo Nordisk Haemophilia Foundation (NNHF) was founded in 2005 by Novo Nordisk, a global Danish pharmaceutical company. NNHF expresses Novo Nordisk’s commitment to corporate social responsibility.

Realising that vast differences in care and treatment standards exist, depending on where concerned people live, was the starting point of the company’s considerations. Moving haemophilia and allied bleeding disorders higher on the global healthcare agenda and providing access to care are key elements of Novo Nordisk’s approach to impacting change in disease areas in which it can make a difference as a company and good corporate citizen.

Based in Zurich, Switzerland, NNHF receives approximately CHF 3.2 million per year from its main benefactor, Novo Nordisk. Other benefactors are permitted by the foundation’s Council.


Related content

Find out more about haemophilia and allied bleeding disorders
Read more

Read about all our programmes in our latest NNHF Activity Report
Read more

Find out which countries we operate in
Read more

Find out more about NNHF's identity
Read more

Our code of conduct
Read more

See all NNHF documents